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Highlights 
 Patients had strong pre-existing beliefs about opioids being effective medicines.
 Many patients were surprised by results of medication treatment.
 Patients highly valued the trial’s personalized pharmacist care management model.
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Abstract 
Chronic musculoskeletal pain is a major public health problem. Although opioid prescribing for 
chronic pain has increased dramatically since the 1990s, this practice has come under scrutiny 
because of increases in opioid-related harms and lack of evidence for long-term effectiveness. 
The Strategies for Prescribing Analgesics Comparative Effectiveness (SPACE) trial was a 
pragmatic 12-month randomized trial comparing benefits and harms of opioid versus non-
opioid medications for chronic musculoskeletal pain. The current qualitative study was 
designed to better understand trial results by exploring patients’ experiences, including 
perceptions of medications, experiences with the intervention, and whether expectations were 
met. Thirty-four participants who were purposefully sampled based on treatment group and 
intervention response participated in semi-structured interviews. The constant comparison 
method guided analysis. Results revealed that participants often held strong beliefs about 
opioid medications, which sometimes changed during the trial as they gained experience with 
medications; participants described a wide variety of experiences with treatment effectiveness, 
regardless of study group or their response to the intervention; and participants highly valued 
the personalized pain care model used in SPACE.  
Perspective: SPACE trial results indicated no advantage for opioid over non-opioid medications. 
Qualitative findings suggest that, for patients in both treatment groups, pre-existing 
expectations of medications and of anticipated improvement in pain shaped experiences with 
and responses to medications. In addition, the personalized pain care model was described as 
contributing to positive outcomes in both groups.  
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Introduction 
 Chronic musculoskeletal pain is a major public health problem, associated with disabling 
physical and emotional consequences for patients and with significant costs related to medical 
treatment and lost worker productivity.16 Use of opioid analgesics to treat chronic pain has 
increased dramatically in recent years,7, 25 paralleled by increases in opioid-related harms, 
including addiction and death.1, 23, 34 While harms of opioids have become apparent, evidence 
for long-term effectiveness of opioids for chronic pain is lacking; a recent systematic review 
found no randomized trials that examined effects of opioids on pain, function, or quality of life 
at one year or longer.10 
 Despite the lack of evidence on the long-term effectiveness of opioids, these 
medications are frequently perceived to be strong, powerful pain relievers.2,3,8 Such 
perceptions may have an important influence on patients’ responses to opioid medications; 
evidence suggests that patients’ expectations can indeed shape outcomes.32,40  This may be 
especially true for pain outcomes, which are subjective and self-reported. For example, in a 
pooled analysis of four acupuncture trials for migraine, tension headache, low back pain, and 
osteoarthritis, patients who had higher treatment expectations were more likely to have a 
clinical response to the intervention.26 In a secondary analysis of behavioral physical therapy 
interventions for patients with low back pain, authors found a significant positive association 
between patient treatment expectations and improvements in pain intensity and disability.18 
Studies such as these suggest that patients’ responses to opioids might be similarly influenced 
by their expectations of the effectiveness or strength of these medications. 
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The Strategies for Prescribing Analgesics Comparative Effectiveness (SPACE) trial was a 
pragmatic trial comparing the benefits and harms of opioid versus non-opioid medication 
therapy over 12 months for patients with chronic back pain or hip or knee osteoarthritis pain.21 
Main SPACE trial results indicated that opioid therapy did not differ from non-opioid therapy on 
the primary outcome of pain-related function over 12 months, although most patients in both 
treatment groups experienced improved function from baseline to 12-month follow-up. 
Additionally, non-opioid medications were significantly better than opioids on pain intensity 
and tolerability outcomes. 20  
Given evidence suggesting that treatment expectations can influence treatment 
response, we sought to gain a more complete understanding of the potential role of 
expectations in the SPACE trial. This was particularly important because participants were not 
masked to their assigned treatment group, and main outcomes were self-reported. To better 
understand expectations and subjective experiences with the SPACE trial, we conducted a 
qualitative, post-intervention evaluation. Qualitative evaluations and mixed-methods 
approaches to clinical trials are increasingly being used to help to understand and interpret 
clinical trial results. Such approaches can help to elucidate possible reasons underlying 
quantitative results and can be especially useful for understanding outcomes of complex 
interventions such as those used in pain management.11 Qualitative data also have the 
potential to capture aspects of participants’ experiences with an intervention that are not easily 
measured quantitatively, potentially revealing avenues for future lines of inquiry or important 
clinical implications.30, 31  
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 For this post-intervention evaluation, we conducted in-depth qualitative interviews with 
purposefully sampled SPACE participants in an effort to understand patients’ experiences with 
the SPACE trial, including their views and anticipated benefits of opioids versus non-opioids, 
experiences with the intervention, and to what extent expectations were met after completing 
the study.  
Methods 
The SPACE Study. The Strategies for Prescribing Analgesics Comparative Effectiveness (SPACE) 
trial was a pragmatic randomized comparative effectiveness trial conducted with patients in 
multiple VA primary care clinics from 2013 to 2015. The study’s objective was to compare 
benefits and harms of opioid therapy versus non-opioid medication therapy over 12 months for 
patients with moderate-to-severe chronic back pain or hip/knee osteoarthritis pain who were 
not already receiving regular opioid therapy. Accordingly, eligible patients were randomized to 
either the opioid or non-opioid intervention group. Both groups received active “treat to 
target” medication management delivered by a study pharmacist within a telecare 
collaborative management model.22 The two study groups differed only in the medications 
offered, and multiple medications were available within each group. Medications were tailored 
to individual patient preferences and adjusted as needed to reach therapeutic targets. After 
intervention completion, most participants in the opioid group worked with the study 
pharmacist to taper off opioids and transition to non-opioid pain medications. Participants’ 
medication management was subsequently returned to their primary care provider. Procedures 
were approved by the Minneapolis VA Institutional Review Board and Research and 
Development Committee. Informed consent was obtained from all participants. See Krebs et 
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al.21 for detailed study protocol, recruitment outcomes, and participant characteristics. Of 240 
patients who were randomized, 234 completed the study, and all but one patient received 
medication treatment in their assigned study group.  
Eligibility and Recruitment. Participants who completed the 12-month trial and were willing 
and able to return to the medical center for a qualitative interview were eligible to participate 
in this qualitative study. Patients were purposefully sampled from trial completers to reflect 
four subgroups defined by two variables: treatment group assignment (opioid group or non-
opioid group) and pain treatment response (responder or non-responder).  Pain treatment 
response was defined as improvement of at least 30% on the Brief Pain Inventory (BPI) 
Interference scale19, 38  from baseline to the 12-month follow-up assessment.  We sought to 
obtain at least 5-8 participants in each of the four subgroups; this size is consistent with 
published recommendations on adequacy of subgroup sample size required for saturation (i.e., 
sampling to the point of redundancy in the data, when no new theoretical insights emerge) and 
allows searching for disconfirming evidence.24 In addition to sampling based on these criteria, 
we selected a diverse sample in terms of age, sex, and race, in an effort to obtain a wide range 
of experiences and viewpoints. Patients were invited to participate in the interviews within 2 
months of intervention completion, to optimize recall of study experiences. Once patients 
agreed to participate, arrangements were made for a face-to-face interview. Participants were 
compensated $20 after completing the interview. 
Interviews. All interviews were conducted face-to-face in a private room. Two experienced 
qualitative interviewers (MD and AJ) conducted several interviews together, to ensure 
consistency among interviews, before conducting the remainder of the interviews individually. 
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Interviews took 45-60 minutes, were semi-structured, and followed an interview guide of open-
ended questions. The interviews started with general questions about pain and pain 
management (e.g., how pain first started, past pain treatments) and then shifted focus to 
experiences in the SPACE trial, including reasons for participation, goals for pain management, 
preferences for treatment group assignment, opinions about pain medications, and changes in 
pain since starting the study. All interviews were digitally audio-recorded, professionally 
transcribed, checked for accuracy, de-identified, and imported into NVivo 10 for analysis. 
Data Analysis. All authors participated in data analysis, which was led by the first author (MM) 
and guided by an inductive approach using the constant comparison method.9, 27  This iterative, 
consensus-based process consists of two broad phases, open coding and focused coding. During 
open coding, team members read all transcripts, noting common, recurrent, and salient themes 
within and between transcripts. This process led to the development and subsequent 
refinement of a code list. Once the codes were stable and consistent, analysts conducted 
focused coding, in which codes derived in the first analytic phase were applied to all transcripts. 
Analysts divided all transcripts evenly, coding every fourth transcript in common and meeting 
to compare coding. Discrepancies were resolved by consensus. Analysts were masked to the 
overall quantitative results of the SPACE trial until qualitative data analysis was completed. 
Because of the nature of the interviews, analysts were not blinded to assigned treatment 
group. 
 The analytic team employed procedures established in the literature on qualitative 
methods to ensure rigor and validity. Procedures included engaging in reflexivity (e.g., 
questioning interpretations, becoming aware of one’s own expectations in the data), depth of 
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description (i.e., seeking out rich, particular details of participants’ words and experiences), and 
actively looking for alternative interpretations of the data that might challenge study findings 
and conclusions.4, 9, 12, 13  
Results 
 Thirty-four patient participants were interviewed, at which point saturation was 
reached. Participants were 6 women and 28 men, ranging in age from 31 to 78 years 
(mean=58.9, SD=12.5). Demographics for the full SPACE trial are reported in Krebs et al.20 Two 
participants self-identified race as black or African-American, 31 as white, and one participant 
identified with multiple categories. Eighteen participants were in the opioid group, including 10 
non-responders and 8 responders, and 16 were in the non-opioid group, including 7 non-
responders and 9 responders. In the interviews, participants discussed their expectations of the 
intervention, including beliefs about opioids and non-opioids, whether they had a preference to 
receive opioids or non-opioids, and why. Participants discussed the degree of pain relief and 
other changes they experienced during and after the intervention, and how these results 
aligned with their original expectations.   
The participant quotes that follow are labeled according to the subgroups used for 
purposeful sampling (i.e., opioid group or non-opioid group; responder or non-responder). 
Expectations of Opioid and Non-Opioid Medications 
Interviewers asked patients to recall their preferences for treatment group (i.e., opioids 
or non-opioids) at the beginning of the study. Several patients indicated a preference for the 
opioid group because of the perception that opioids are “stronger.” 
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 I definitely wanted the opiate *group+… I guess I was just thinking that it would 
be stronger medicine. (13440, opioid group; responder)  
  
 I was kind of hoping that it would be the narcotics because…usually narcotics are 
stronger than non-narcotics, and I was hoping that I could get something that 
would be stronger. (11083, non-opioid group; responder) 
  
 
 There’s a reason it’s controlled—usually because it’s better. So in my mind, when 
you’re in serious pain, you need serious medication—which, serious medication 
is opioids. (12009, non-opioid group; responder)  
   
Others voiced concerns about being randomized to the opioid group. Many feared addiction. 
 
 I had hesitations about the opioid group…I was concerned about long-term use, 
addiction issues, because, you know, if you feel that good, are you really going to 
want to stop, ever? And I can answer that honestly, no, you don't want to stop. 
You feel good. (13606, opioid group; non-responder)  
  
 I had an opinion that I didn’t want to end up on anything that could become 
addictive. Hydrocodone works. I’m not going to say it doesn’t. But if every time I 
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took one I was afraid, oh my God, would this be the one that makes me 
addicted? (10882, non-opioid group; responder)  
 Impairment while on opioids was another worry. One patient indicated that, although 
he believed opioids might be more effective, he was concerned about how they might affect his 
job working on school buses: 
 Narcotics can lead to a lot of trouble. You're driving, you're taking [an opioid 
medication], and you get behind the wheel because you have to drive 
somewhere. Now you are driving on an illegal drug…You have to take it because 
you hurt really bad in the morning, for whatever reason you have to drive… 
you've put yourself open for a liability of massive proportions. For a non-
narcotic, if it only works half as well, it still allows you to retain control and not 
be as drowsy. It's safer to not be on a controlled substance. Especially when you 
have a drive like I do. I mean, I work on school buses. I wouldn’t even dream 
about taking [an opioid] at work. (11161, non-opioid group; responder)  
 
 Some negative perceptions of opioids were influenced by past personal experiences or 
those of friends or family.  
 
I had more of like a hallucinogenic type of reaction [to codeine]. It really freaked 
the hell out of me. And I did not do well. (11790, non-opioid group;  non-
responder)  
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I’ve just seen my friends and family who have those problem, they can’t just 
quit...I’ve got an Army buddy of mine who still does opioids just because he 
thinks it makes him a nicer person. That’s him. There’s always concern about 
getting addicted to pills. (13103, opioid group; responder)  
 
 Some patients reported no concerns about opioids. One patient, when asked if he had 
any concerns about being randomized to the opioid group, replied, 
 
 I wasn't worried about if I ended up in the opiate group. I wasn't worried about 
the addiction situation because I don't like drugs to begin with. And I don't drink, 
I don't smoke…so I figured, I looked at it as, you know, it's just a pill you've got to 
put in your mouth…I mean, I didn't think it was going to kill me or anything. 
(10976, opioid group; non-responder)  
  
 Another patient believed that her past addictions better equipped her to resist 
addiction to opioids: 
The only concern I had was that I do have a very addictive nature, but I also am a 
survivor…And so as far as addiction…I’ve come through that kind of stuff before, 
and I know that I’ll be able to make it through. (11082, opioid group; non-
responder)  
 
Experiences with Opioid Treatment 
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 Participants in the opioid group described a variety of outcomes of their pain 
medication treatment. Notably, the subjective experience of benefit or lack of benefit that 
patients reported did not always match their responder status based on change in numeric 
scores.   
 
Some patients described good results from opioids. 
Patient: So, my [pain] control has been great. 
Interviewer: Do you have any long-term concerns about being on opioids?  
Patient: No. (13413, opioid group; responder)  
 
 I don't think I would've had as quick of feel-good results [in the non-opioid 
group+… When I was on the first med, it really got me energized. It improved my 
outlook…it got me wanting to do more and be more. (13606, opioid group; non-
responder)  
 
 I just want[ed] to be able to walk around the block. Then I wanted to [walk] a 
half mile. And then, you know, I constantly increased that and now I'm up to four 
miles a day, six days a week… And it was all because of the medication. (10976, 
opioid group; non-responder)  
This participant went on to say later in the interview, “The relief was way better than what I 
ever thought it would be.” (10976, opioid group; non-responder) 
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 Some non-responders in the opioid group described opioids as working in the short 
term, but losing effect over time.  
 Participant: When I first started, it would take the pain away and it would be 
great, but now when I take the medications, it still helps with the pain, but 
there’s still pain. It’s more tolerable…They’re worn off. They are wearing down 
basically. 
 Interviewer: Did the medications work the way you thought that they would? 
 Participant: They did at first…but then they wore down to where it’s not as much 
as I would’ve hoped for, but enough to keep me going. (11082, opioid group; 
non-responder)  
 
 I had immunity…it's less effective. But in the beginning, it was much better. 
(11305, opioid group; non-responder)  
 
 I thought the morphine was really working well up until I fell. And…then it didn't 
cut through the back pain. (11431, opioid group; non-responder)  
 
 Other patients, including some classified as responders, reported disappointment with 
the relief they got from opioids. 
I guess I didn't even know what to expect. It helped, but it didn't fix it. (10987, 
opioid group; responder) 
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I thought I’d get more relief from *the opioid+… *Now+ I’m taking two tablets *of 
acetaminophen] three times a day, and that seems to be working just as well as 
[the opioid] did. (11422, opioid group; responder) 
 
 Some responders in the opioid group did not want to continue taking opioids because of 
concerns about addiction or undesirable side effects.  
 I have a niece that got hooked on opioids, so it scared me. (10987, opioid group; 
responder) 
One patient described how he reduced his opioid dose himself, during the study, because of 
addiction concerns. 
 These drugs are addictive, okay? They take control of your life. These opioids are 
screwing up your mind. You become addicted. Thank God I weaned off of it 
myself, because I felt that monkey on my back. (13168, opioid group; responder)   
 Another patient explained that the opioids provided pain relief, but interfered with her 
quality of life and ability to reach personal goals. 
 I'm glad I'm not on opiates anymore. They were effective, but it felt like I was 
living my life in a sleepy stupor. I did not like being tired and, you know, I could 
lay down on the floor and fall asleep. My quality of life, I thought, diminished 
because of the opiates. I think, how, why would you want to take these in your 
right mind? How can you even function? I wanted to be a more active participant 
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in my life. I wanted to reestablish friendships and I wanted to get projects done 
around the house. And I felt none of that was going to happen as long as I was 
on those opiates. All I wanted to do was sleep. (13427, opioid group; responder) 
 
 Another opioid responder described undesirable side effects that outweighed benefits 
of opioids. 
  They all worked, everything [the pharmacist] gave me worked… But some of the 
medicines at the beginning, I just didn't like the feeling I had. And I think the first 
one, which was the morphine, more scared me than anything… All I got was like 
a woozy feeling. So, I wasn't really on that one too long. A month or two, I think. 
And I was scared to take—it worked. It worked real good. But it was the 
constipation. (13981, opioid group; responder) 
 Other patients, including responders, reported that opioids did not provide much pain 
relief.  
 It’s almost like it would deaden my mind and make me like I was drunk or loopy. 
It wouldn’t actually affect the pain, because you’d still be all googly, but you still 
knew you had the pain. (11239, opioid group; non-responder) 
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 I really don't know if it's doing any good. Well, like I say, just like the morphine, 
they don't eliminate the pain. You know, I'd still be on the morphine if it 
eliminated the pain. It don't.  (13168, opioid group; responder) 
 
Experiences with Non-Opioid Treatment 
 Some patients described surprise that non-opioid medications were more effective than 
expected.  
 I was hoping to get into *the opioid+ group …But there’s always that thought, it’s 
like, well, hopefully, I won’t get addicted to the stuff. That’s why I was like, I can’t 
believe that ibuprofen, 800 milligrams, solved the problem. (10949, non-opioid 
responder) 
 
 Another patient had hoped for the opioid group because “I knew *opioids+ worked.” He 
said after completing the study in the non-opioid group, “We had a little trouble at first, but 
finally we got them dialed in and it was great. I was really managing my pain well. I was very 
happy after we had it all dialed in and everything.” (13239, non-opioid group; non-responder) 
 One patient who was treated in the opioid group during the study and transitioned to 
non-opioid medications after study completion described his experience with both approaches, 
including his surprise that the non-opioid medications seemed to be as effective as the opioid 
he had been taking.  
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 Patient: Well, the hydrocodone was probably most effective because it was more 
powerful of any that I've taken. And, you know, it does more than just relieve the 
pain on my knee, it relieves anxiety and, you know, a few other things.  
 Interviewer: And, now, when you switched over from the hydrocodone to the 
acetaminophen and lidocaine, were the results any different than what you 
expected?  
 Patient: No, the results were about what I expected. The extra heat on my knee 
that provided some relief and the acetaminophen…between the two of them, it 
did the same about as the hydrocodone. I was a little surprised. (13281, opioid 
group; non-responder) 
 
 A patient in the non-opioid group indicated that he initially believed opioids were 
stronger, but had a good response to an anti-inflammatory medication.  
 
 I thought, I’ll give *the non-opioids+ a try…You have to take hydrocodone 
multiple times a day, and after four to six hours the pain’s back, then you have to 
take the meds again. Where with the meloxicam I can take it in the morning and 
if I forget to take my morning dose the next day, I’m still fine. I can go easily 24 
hours on one dose…without noticing any pain. (12009, non-opioid group; 
responder) 
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 Other patients described positive effects of non-opioid medications on their activities. 
For example, the following patient described how his activity improved after he joined the 
SPACE study: 
 I wanted to be active again. It was killing me—just as soon as I came home from 
work, I was completely exhausted from not sleeping, you know, getting two, one 
to two hours of sleep from just holding my knee, trying to figure out any way to 
stop the pain. And going through the pain study that took a year, but finally it’s 
like thank goodness. 
He went on to explain that ibuprofen turned out to be most effective medication for him. 
Smooth sailing. Yep… And I’ve gone from not being able to exercise to walking 
five miles a day now, every morning. (10949, non-opioid group; responder) 
 
 Other patients similarly noted they were able to be more active and had improved 
fitness since being treated in the non-opioid group.  
 I have no problem with the lawn work now. I’ve increased my walking, and that’s 
pretty good. (11417, non-opioid group; responder) 
 
 I can pick my kid up, throw him around, spin him around, whatever, and I feel 
great….I even feel like getting teary because I’m just so happy. I am. I’m able to 
do a lot of things that I couldn’t. A lot more things than I thought I would be able 
to even *do+….I’m also a lot more muscular than I was a year and a half ago, too.  
He went on to describe how his results surprised him. 
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 I was expecting it not to be 180-degree turn because I went from being just 
miserable every day to being just, for the most part, happy. I can basically just 
bounce right out of bed. 
In addition, this patient described a change in his beliefs about opioid and non-opioid 
medications after participating in the SPACE study. 
 I assumed…opioids were powerful. So they were necessary for extreme pain 
when that’s not the case. So I do have a lot more respect, I guess, for non-
opioids.  (12009, non-opioid group; responder) 
 
 One patient described surprise at the effectiveness of a topical cream: 
 I didn't really expect the topical cream to work, to be honest. I thought 
something had to be ingested, *but+…it was a site-specific pain. And I didn't really 
think about that at the beginning of the study. You start numbing it up, you get 
the pain receptors used to this burning and eventually once they're used to the 
burning, they don't—your receptors aren't as active, it doesn't hurt as much. 
(11161, non-opioid group; responder) 
 
 Some patients described insufficient relief from non-opioid medication treatment.  
 I was hoping that I could get back some of the things that I lost like, because of 
my pain I had to quit my volunteer job at the food shelf. I was hoping I could get 
back to that, but so far that’s not been the case. I was hoping I would be able to 
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go out for walks again, but it’s been so painful that I’ve not been able to do that. 
(11083, non-opioid group; responder) 
 
 Another patient described some improvement in pain, but not enough: “I made 
progress, but I’m still frustrated with the pain.” (11677, non-opioid group; non-responder) 
 
Experiences with Pain Care Management  
 Participants in both study treatment groups described the value of the pain care 
management approach used in the SPACE trial. A number of patients from both study arms 
commented on the individualized treatment they received from the clinical pharmacist who 
managed their medication regimen. 
Interviewer: What was the most important thing that you got from participating 
in SPACE? 
Patient: Individual treatment. I mean, [the pharmacist+ was great… And she 
listened to me. I mean, she wouldn’t do anything I didn’t want to do. She 
wouldn’t coax me into any which way. I had to want to do it. It had to be my 
choice. (11788, non-opioid group; responder)  
 
[The study pharmacist] was wonderful…It was nice to see her and…it calmed me 
down a little bit about worrying about taking [opioids] and being on them for 
year. (10987, opioid group; responder)  
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 Of particular note, one participant attributed his improvement during the trial more to 
the support of the pharmacist than to the opioid medications he was prescribed. When asked if 
he thought his results would have been different if he had been in the non-opioid group, he 
responded, “I think if the physical or the verbal support with [the pharmacist] was the same, I 
don’t think there would’ve been a difference taking a bunch of Tylenol as opposed to the 
opioids.” (13103, opioid group; responder)  
 
Discussion 
  The goal of this qualitative follow-up study was to further understanding of SPACE trial 
results by elucidating participants’ expectations of and subjective experiences with the trial 
interventions. The primary result of the SPACE trial was that opioid therapy did not differ from 
non-opioid therapy for pain-related function. Notably, most patients in both treatment groups 
had improvement in function from baseline to 12-month follow-up. In addition, pain intensity 
and medication-related adverse symptom outcomes were significantly worse for opioids 
compared with non-opioids, but differences between groups were small.20  Results of in-depth 
interviews with patients have several key implications for interpretation of the main SPACE trial 
results.   
Beliefs about Opioid and Non-Opioid Medications 
 First, we found that many patients expressed strongly held beliefs about the relative 
effectiveness and risks of opioid and non-opioid medications and that some patients noted 
changes in these beliefs over time, based on experiences during the trial. Participants 
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frequently described beliefs that opioids were “stronger,” with one participant compellingly 
describing them as “serious medication” for “serious pain.”  Some participants expressed fears 
of addiction or impairment. Others had concerns based on their past experiences with opioids, 
or those of friends or family. Interestingly, patients often expressed these concerns while 
indicating their belief in opioids as effective, powerful medications. These findings corroborate 
widespread perceptions of opioids as powerful “painkillers,” which is how they are commonly 
described by public health officials, consumer advocates, and journalists.2,3,8  These qualitative 
findings are also consistent with quantitative pre-randomization perceptions of the two 
treatment arms in SPACE; overall, participants reported perceiving opioids as substantially 
more effective and somewhat less safe than non-opioid medications.21 
Interviews also depicted how patients’ perspectives sometimes changed over time, as 
they gained experience with medications. Some patients in the opioid group expressed 
disappointment in the results of opioids, describing expectations for greater relief than they 
experienced or diminishing effectiveness as time went on. Likewise, some patients in the non-
opioid group described surprise that non-opioids could work as well as they did. Current opioid 
prescribing guidelines recommend discussing patient expectations and establishing realistic 
goals for pain and function prior to initiating therapy.14 Our findings support this approach. 
Because patients and health care providers were not masked to SPACE treatment 
assignment, expectations about opioid and non-opioid medication interventions may have 
influenced the primary patient-reported outcomes in the trial. If present, bias due to positive 
expectations about opioid effectiveness would likely favor the opioid treatment group.26 Our 
qualitative results illuminate how preconceptions may have been at least partially countered by 
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experience over the course of the trial; this phenomenon has been previously described and 
could hypothetically ameliorate a biasing effect of expectations on reported outcomes over 
long-term follow-up.36 
Experiences with Treatment Effectiveness 
A second important implication for the SPACE main trial results is that participants 
described a wide variety of experiences with treatment effectiveness, regardless of their 
treatment group assignment (i.e., opioid or non-opioid) and whether they met the threshold for 
responder status (i.e., 30% improvement in BPI interference). Some patients who were 
considered non-responders described improvement in pain and physical function, whereas 
some of those considered to be responders described inadequate improvement. Because pain, 
functional impairment, and well-being are inherently subjective concepts, we do not find it 
surprising that objective and subjective measures of treatment outcomes were incompletely 
aligned. Furthermore, patients who met the 30% improvement threshold may have been 
disappointed if this was less improvement than they had anticipated. The mean pre-
randomization self-reported rating of “likely personal improvement” during the study was 7.5 
on a scale of 0 “no improvement” to 10 “a great deal of improvement.” Although we did not ask 
patients in this study to quantify acceptable or desirable levels of improvement, prior research 
has demonstrated that patients’ expectations for the magnitude of improvement are 
sometimes higher than expected benefits of existing therapies.33, 35  Interviews also suggested 
that pain relief alone was not sufficient for some patients to consider medications effective. 
Several patients indicated they had less pain while taking opioids, but still chose to discontinue 
them because of concerns about addiction, undesirable side effects, or interference with 
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function and quality of life. These findings highlight the clinical importance of assessing more 
than just pain intensity when evaluating effectiveness of prescribed pain treatments. While 
pain intensity scores provide an important metric by which to gauge a patient’s improvement, it 
is also important to engage patients in a discussion of what such scores mean in the context of 
their own lives and experiences. 
The SPACE Pharmacist Care Model 
 Finally, we found a strong theme of satisfaction with the pain care model—personalized 
medication management delivered by a clinical pharmacist—used in both arms of the SPACE 
trial. Many patients described this personalized contact as just as important as the medications 
they were taking. The views of these SPACE participants are consistent with research indicating 
that effective patient-provider communication is inextricably linked to important, measurable 
outcomes, including patient satisfaction, adherence to treatment, and relief of symptoms.5, 6,, 15, 
17, 37  
The importance of a caring clinician providing tailored advice and support has been 
corroborated in other studies of patients with chronic pain. Participants in a randomized trial 
consisting of medication management, brief cognitive behavioral therapy, and pain self-
management education delivered by a nurse care manager identified the nurse as key to 
successful pain management, fulfilling three specific roles: helping patients find what works for 
their pain, holding patients accountable for their pain management, and motivating and 
providing emotional support.29 In another study involving pain self-management and 
medication management for patients with chronic pain and depression, the nurse care manager 
was similarly identified as critical to successful pain management.30 Patients in both of these 
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studies emphasized that the self-management, medication management, or other clinical care 
provided were not the only “active ingredient” in the minds of participants, but that the 
clinicians delivering the interventions played an integral role as well. In the same way, the 
personalized care and measurement-based medication management from the pharmacist care 
manager is likely to be at least partially responsible for the clinical response rates in the SPACE 
study. Exposing both arms to this care management approach, with similar contact rates and 
pharmacist time in both arms, effectively controlled for communication and therapeutic 
alliance factors that could bias findings if one group received more intensive contact than the 
other.  
This study is limited in that all participants were VA patients in one metropolitan area 
who agreed to enroll in a randomized controlled trial. As a result, qualitative results might not 
be applicable to other patients with chronic pain taking medications in a non-research 
environment.28, 39 In addition, because patients were interviewed at the same medical center 
where they received the SPACE intervention, it is possible that they felt more comfortable 
reporting only positive experiences. However, because some were critical of the intervention, 
and because participants provided rich, detailed descriptions of their experiences with the 
intervention, rather than speaking in generalities, we believe that such a social desirability bias 
is unlikely. 
Conclusions 
 The SPACE trial, the first randomized controlled trial to compare long-term outcomes of 
opioid versus non-opioid medications for chronic pain, found no advantage of opioids over 12 
months. Moreover, opioids caused significantly more medication-related adverse symptoms 
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than non-opioid medications.20 The current qualitative study provides important insights that 
help to enhance our understanding of the SPACE trial results. First, the role of expectations 
played a prominent role in patients’ experiences with SPACE. These included expectations that 
opioids are strong, powerful medications, and expectations of pain improvement that may or 
may not have matched the study definition of a clinically-important response (i.e., 30% 
decrease in BPI interference). Together these expectations seemed to shape patients’ 
experiences with and responses to the intervention, leading to results that surprised some 
patients, while others perceived little change. In addition to the role of expectation, patients 
expressed a high degree of satisfaction with the personalized pharmacist care model that 
patients in both study arms experienced. The presence of a caring, responsive clinician seeking 
to improve patients’ pain may in part help to explain why, although opioids showed no 
advantage over non-opioids, patients in both study arms improved.   
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